Richard Malcolm, PhD, has been appointed CEO ofAcurian(Horsham, Pennsylvania), replacing Mark Eisenach, who concluded a four-year tenure as CEO. Malcolm most recently was vice president of business development at Icon Clinical Research, a contract research organization. Acurian is a provider of clinical trial patient and investigator recruitment solutions for the life sciences.

James Barrile has been named executive vice president and chief operating officer for Axya Medical (Beverly, Massachusetts). Most recently, Barrile was CFO for Trans1 and provided consulting services to Warburg Pincus. Barrile also was a co-founder and the CFO at Innovasive Devices. Axya develops products to facilitate minimally invasive, arthroscopic surgery. It has developed a suture welding system that eliminates the process of deploying suture knots through a small scope.

Dr. David Galas will join the global R&D organization Battelle (Columbus, Ohio) as vice president and chief scientific officer for biological and life sciences. Galas brings more than 35 years of experience to Battelle, including academic, corporate and government research positions. Galas was among the early leaders in the U.S. Human Genome Project and, from 1990 to 1993, he led the DEO component of the project.

Brian Ferrell will head the U.S. sales organization of CareTech Solutions (Troy, Michigan), an information technology and health information management outsourcing company for hospitals and health systems. Ferrell brings more than 20 years of sales experience to CareTech, including regional vice president of a major supplier of diagnostic equipment and healthcare information technology solutions.

Michael Steele has joined Corautus Genetics (Atlanta) as vice president of business development, and will serve as a corporate officer. Steele most recently served as corporate vice president of Life Therapeutics. Corautus Genetics is a clinical-stage biopharmaceutical company developing gene transfer therapy products for the treatment of cardiovascular and peripheral vascular disease.

Thom Skinner has been named CFO of DiagnoCure (Quebec City, Quebec), a provider of cell-based assays and molecular diagnostics for the early detection of cancers. Most recently, Skinner served as interim CFO for Aventis Pharma and integration officer for Sanofi-Synthelabo Canada.

Robert Jordan has been appointed executive vice president of eCardio Diagnostics (The Woodlands, Texas), a provider of advanced technology cardiac arrhythmia monitoring. Most recently, Jordan served as an executive with Diagnostic Monitoring Associates.

Eugene Fife, chairman and director of Eclipsys (Boca Raton, Florida), has been named to the additional roles of president and CEO. Fife has been the chairman of Eclipsys since January 2003 and a director since 1997. He succeeds Paul Ruflin, who is leaving the company. Fife was formerly a general partner of Goldman Sachs, where he served as a member of the firm’s management committee and as chairman of Goldman Sachs International. Eclipsys, which calls itself “The Outcomes Company,” is a provider of clinical, financial and management information software and service solutions to more than 1,500 healthcare facilities.

Christian Henry was named vice president and CFO of Illumina (San Diego), effective June 6. Henry most recently served as CFO for, and prior to that was vice president, finance and corporate controller of Affymetrix. He will replace Timothy Kish. Kish served five years as Illumina’s CFO and will provide consulting services to the company to ensure a smooth transition. Illumina is developing tools that permit large-scale analysis of genetic variation and function.

Mark Gardner has been promoted to chief marketing officer for Invitrogen (Carlsbad, California). He has served Invitrogen in several roles since 2003, most recently as vice president of commercial marketing. Invitrogen provides life science technologies for disease research, drug discovery and commercial bioproduction. Invitrogen’s own R&D efforts are focused on all major areas of biological discovery, including functional genomics, proteomics, bioinformatics and cell biology.